In both prostate cancer and benign regions, RUNX1 is highly expressed in the nucleus, however, the labeling index (LI) of RUNX1 is decreased in prostate cancer tissues with a high Gleason score (Supplementary Table 1). Here, RUNX1 is linked to prostate carcinoma.